Mark Holodniy

16.4k total citations · 3 hit papers
237 papers, 9.5k citations indexed

About

Mark Holodniy is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Mark Holodniy has authored 237 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Infectious Diseases, 87 papers in Epidemiology and 75 papers in Virology. Recurrent topics in Mark Holodniy's work include HIV/AIDS drug development and treatment (79 papers), HIV Research and Treatment (73 papers) and HIV/AIDS Research and Interventions (65 papers). Mark Holodniy is often cited by papers focused on HIV/AIDS drug development and treatment (79 papers), HIV Research and Treatment (73 papers) and HIV/AIDS Research and Interventions (65 papers). Mark Holodniy collaborates with scholars based in United States, Canada and United Kingdom. Mark Holodniy's co-authors include Mark A. Winters, David Katzenstein, Douglas K Owens, Jordan Raphel, Stuart B. Goodman, Sarah C. Heilshorn, Zhuang Liu, Hongjie Dai, Andrew Zolopa and Edwin D. Charlebois and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Mark Holodniy

230 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population

2000 864 citations Mark Holodniy et al. profile →
Rapid identification of pathogenic bacteria using Raman spectroscopy and deep learning

2019 592 citations Mark Holodniy et al. profile →
Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants

2016 562 citations Mark Holodniy et al. profile →

Peers

Countries citing papers authored by Mark Holodniy

Since Specialization

Citations

This map shows the geographic impact of Mark Holodniy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Holodniy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Holodniy more than expected).

Fields of papers citing papers by Mark Holodniy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Holodniy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Holodniy. The network helps show where Mark Holodniy may publish in the future.

Co-authorship network of co-authors of Mark Holodniy

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Holodniy. A scholar is included among the top collaborators of Mark Holodniy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Holodniy. Mark Holodniy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An update on drug–drug interactions in older adults living with human immunodeficiency virus (HIV) 2024 ·Expert Review of Clinical Pharmacology ·(unknown), (unknown), (unknown), Mark Holodniy, Aarthi Chary	1
2	Risk of Hospitalization and Mortality Following Medically Attended Norovirus Infection—Veterans Health Administration, 2010–2018 2023 ·Open Forum Infectious Diseases ·Jordan Cates, Cristina V. Cardemil, Sara A. Mirza, Ben Lopman, Aron J. Hall, Mark Holodniy, Cynthia Lucero‐Obusan	1
3	Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case–control study among US veterans 2022 ·BMJ Open ·Yinong Young‐Xu, (unknown), Héctor S. Izurieta, Caroline Korves, (unknown), Jeremy Smith, (unknown), Mark Holodniy, David O. Beenhouwer, Maria C. Rodriguez‐Barradas, Sheldon T. Brown, Vincent C. Marconi	20
4	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study 2020 ·PLoS Medicine ·Christopher T. Rentsch, Farah Kidwai‐Khan, Janet P. Tate, Lesley S. Park, Joseph T. King, Melissa Skanderson, Ronald G. Hauser, Anna Schultze, Christopher I Jarvis, Mark Holodniy, Vincent Lo Re, Kathleen M. Akgün, Kristina Crothers, Tamar H. Taddei, Matthew S. Freiberg, Amy C. Justice	234
5	COVID-19–Related Hospitalization Rates and Severe Outcomes Among Veterans From 5 Veterans Affairs Medical Centers: Hospital-Based Surveillance Study 2020 ·JMIR Public Health and Surveillance ·Cristina V. Cardemil, Rebecca M. Dahl, Mila M. Prill, Jordan Cates, Sheldon T. Brown, (unknown), Vincent C. Marconi, (unknown), Maria C. Rodriguez‐Barradas, (unknown), David O. Beenhouwer, (unknown), Mark Holodniy, Cynthia Lucero‐Obusan, Neha Balachandran, Aron J. Hall, Lindsay Kim, Gayle Langley	20
6	Notes from the Field: Unexplained Dermatologic, Respiratory, and Ophthalmic Symptoms Among Health Care Personnel at a Hospital — West Virginia, November 2017–January 2018 2019 ·MMWR Morbidity and Mortality Weekly Report ·(unknown), Mark Holodniy, Marie A. de Perio, Kiran M. Perkins, Isaac Benowitz, David J. Jackson, Ian Kracalik, Michael P. Grant, Gina Oda, Krista M. Powell	1
7	Carbon monoxide poisoning surveillance in the Veterans Health Administration, 2010–2017 2019 ·BMC Public Health ·Gina Oda, (unknown), Cynthia Lucero‐Obusan, Patricia Schirmer, Mark Holodniy	7
8	Epidemiologic Review of Veterans Health Administration Patients with Isolation of Nontuberculous Mycobacteria after Cardiopulmonary Bypass Procedures 2017 ·Infection Control and Hospital Epidemiology ·Gina Oda, (unknown), Cynthia Lucero‐Obusan, Patricia Schirmer, Hasan Shanawani, (unknown), Mark Holodniy	5
9	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation 2016 ·Journal of Virology ·Soo‐Yon Rhee, Kris Sankaran, Vici Varghese, Mark A. Winters, Christopher B. Hurt, Joseph J. Eron, Neil Parkin, Susan Holmes, Mark Holodniy, Robert W. Shafer	68
10	New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Author Names 2012 ·Annals of Internal Medicine ·Shan Liu, Lauren E. Cipriano, Mark Holodniy, Douglas K Owens, Jeremy D. Goldhaber‐Fiebert	1
11	Clinically Significant Drug Interactions in Younger and Older Human Immunodeficiency Virus‐Positive Patients Receiving Antiretroviral Therapy 2011 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), (unknown), Mark Holodniy	24
12	Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), Dieter Ayers, Joel Singer, P. Richard Harrigan, Sheldon T. Brown, Tassos C. Kyriakides, D. William Cameron, Brian Angus, Mark Holodniy	16
13	Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy 2008 ·Journal of Interferon & Cytokine Research ·Richard T. Davey, Peter Pertel, Alice Benson, Delanie J. Cassell, Brian Gazzard, Mark Holodniy, Jacob Lalezari, Yves Lévy, Ronald T. Mitsuyasu, Frank J. Palella, Richard B. Pollard, Prabhu Rajagopalan, Michael S. Saag, Robert A. Salata, Beverly E. Sha, Shurjeel Choudhri	5
14	Frequency of HIV Screening in the Veterans Health Administration: Implications for Early Diagnosis of HIV Infection 2008 ·AIDS Education and Prevention ·Ronald O. Valdiserri, Fred H. Rodriguez, Mark Holodniy	8
15	Relationship Between Antiretroviral Prescribing Patterns and Treatment Guidelines in Treatment-Naive HIV-1-Infected US Veterans (1992-2004) 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mark Holodniy, John Hornberger, (unknown), (unknown), Thomas MaCurdy, (unknown), Paul A. Volberding, Lawrence Deyton	23
16	Simultaneous Genotyping and Species Identification Using Hybridization Pattern Recognition Analysis of Generic Mycobacterium DNA Arrays 1998 ·Genome Research ·T Gingeras, Ghassan Ghandour, Eugene Wang, Anthony Berno, Peter M. Small, Francis Drobniewski, David Alland, Edward Desmond, Mark Holodniy, Jörg Drenkow	190
17	Phenotypic and Genotypic Testing in Clinical Practice 1998 ·AIDS Patient Care and STDs ·Mark Holodniy	1
18	Polymerase Chain Reaction for the Diagnosis of HIV Infection in Adults 1996 ·Annals of Internal Medicine ·Douglas K Owens, Mark Holodniy, Alan M. Garber, John Scott, Seema S. Sonnad, Lincoln E. Moses, Bruce Kinosian, J. Sanford Schwartz	9
19	Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. 1991 ·Journal of Clinical Investigation ·Mark Holodniy, David Katzenstein, Dennis Israelski, T. C. Merigan	68
20	Detection and Quantification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction 1991 ·The Journal of Infectious Diseases ·Mark Holodniy, David Katzenstein, Sabyasachi Sengupta, (unknown), (unknown), David H. Schwartz, (unknown), (unknown), T. C. Merigan	133

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact